Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may forecast brain recovery after cardiac arrest

NCT ID NCT07760636

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study investigates whether levels of a protein called neurofilament light chain (NFL) in the blood can predict neurological recovery in people who remain comatose after a cardiac arrest. Researchers will measure NFL at several time points over the first week in the ICU and compare these levels with patients' eventual neurological outcomes, ranging from full recovery to severe disability or death. The goal is to see if NFL could serve as a reliable early marker to help guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Measurement of neurofilament light chain (NFL) levels in blood at multiple time points after ICU admission
What this could lead to
If NFL levels reliably predict outcomes, doctors could better identify which patients may recover and guide care decisions after cardiac arrest.
What could go wrong
This is an observational study, so it cannot prove cause and effect. NFL levels may not be accurate enough to replace current prognostic methods, and results may vary across different patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 270 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Comatose patients after cardiac arrest

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients admitted to the ICU for cardiac arrest, * Patients who regained consciousness following in-hospital or out-of-hospital cardiac arrest, * Patients in a coma upon arrival in the ICU, defined by a Glasgow Coma Scale (GCS) score \<8, * Patients included in the AfterROSC2 cohort, Exclusion Criteria: * Terminally ill patients (death expected within 3 hours of admission to the ICU), * Minors, * Patients under legal guardianship, * Pregnant women, * Patients not enrolled in a social security program, * Prior inclusion in the CINEFIL study, * Restriction of active therapies prior to the first NFL biomarker assay, * Objection by a family member or trusted person, if present

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac arrest (CA) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiac arrest Charcot-Marie-Tooth disease type 1F Coma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac arrest (CA) Comatose Intensive care unit (ICU) admission Return of spontaneous circulation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Medical ICU

    Paris, IDF, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.